For investor audiences and financial/business media only
Pascal Soriot, CEO of AstraZeneca:
Strong revenue growth and positive readouts from high-value NMEs reinforce confidence in 2030 ambition
“We delivered strong growth in Q1 2026, with Total Revenue above $15 billion, demonstrating our consistent commercial execution. We are advancing through our catalyst‑rich period, with positive readouts for four high-value Phase III programmes since our last quarterly results, including first pivotal data for two key new molecular entities (NMEs).”
Downloads
expected to increase expected to increase
The Core Tax rate is expected to be between 18-22%
NMEs under review NMEs in our late‑stage pipeline projects in our pipeline
NMEs or major life‑cycle management in Phase II or Phase III
AstraZeneca reconfirms Total Revenue and Core EPS guidance1
for FY 2026 at CER2, based on the average foreign exchange rates through 2025.
Total Q1 revenue
up 8% to $15.3bn
by a mid-to-high single-digit percentage
Core3 EPS
up 5% at $2.58
by a low double-digit percentage
Pipeline at a glance
4
21
186
118
Matthew Bowden
Company Secretary
AstraZeneca PLC
References
1. The Company is unable to provide guidance on a Reported basis because it cannot reliably forecast material elements of the Reported results, including any fair value adjustments arising on acquisition-related liabilities, intangible asset impairment charges and legal settlement provisions.
2. Constant exchange rates. The differences between Actual Change and CER Change are due to foreign exchange movements between periods in 2026 vs. 2025. CER financial measures are not accounted for according to generally accepted accounting principles (GAAP) because they remove the effects of currency movements from Reported results.
3. Core financial measures are adjusted to exclude certain items. The differences between Reported and Core measures are primarily due to costs relating to the amortisation of intangibles, impairments, legal settlements and restructuring charges.